在本論文中，我們合成二十四個苯並咪唑衍生物來探討其在A549(人類肺癌細胞)、MCF-7(人類乳腺癌細胞)、HEP-G2(人類肝癌細胞)及OVCAR-3(人類卵巢癌細胞)的細胞毒殺性。在OVCAR-3的實驗中，其中有十一個化合物IC50介於10.34 - 14.88 μM低於化療藥物順鉑(cisplatin)的IC50值(16.04 μM)。大部分的受測化合物具有當抗癌藥物的潛力在對抗A549, MCF-7 及 OVCAR-3 等癌細胞，然而化合物7a、8a及9a最具有潛力。化合物7a在對抗這四種癌細胞的IC50值與順鉑接近或是更低。此外，使用流式細胞儀進行OVCAR-3癌細胞週期實驗，結果顯示化合物8a及9a會在G2/M的細胞週期造成阻礙，推斷可能是毒殺細胞的原因之一。總而言之，這新的系列氮取代苯並咪唑衍生物可作為往後抗癌藥物的結構原型。

In an effort to establish new candidates with improved anticancer activity, we report here the synthesis of various series of N- substituted benzimidazole derivatives. The cytotoxicity of these compounds were determined using four cancer cell lines, A549 (human lung carcinoma cell line), MCF-7 (human breast adenocarcinoma cell line), HEP-G2 (human hepatocellular carcinoma cell line) and OVCAR-3 (human ovarian carcinoma cell line). Among the tested derivatives, there were 11 compounds (6c, 6d, 7a, 7b, 7c, 8a, 8c, 8d, 9a, 9b, 9c) possessing between 10.34 and 14.88 μM were lower than 16.04 μM (the IC50 value of cisplatin) for OVCAR-3 cells. Although most compounds examined were quite effective on A549, MCF-7 and OVCAR-3 cells, the compounds (E)-3-phenyl-1-(1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]
imidazol-2-yl)prop-2-en-1-one (7a), (E)-3-phenyl-1-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-
benzo[d]imidazol-2-yl)prop-2-en-1-one (8a) and (E)-1-(1-(3-morpholinopropyl)-1H-
benzo[d]imidazol-2-yl)-3-phenylprop-2-en-1-one (9a) emerged as the most active compounds of this series. In particular, the compound 9a possessing great IC50 values on A549, MCF-7, HEP-G2 and OVCAR-3 cells showed in vitro cytotoxicity similar or even better than cisplatin. Additionally, compound 7a and 8a showed effective cytotoxicity on OVCAR-3 cells and arrested the cells at G2/M at a similar concentration of MTT experiment. Therefore, the result of flow cytometry showed that compound 7a and 8a have abilities to arrest cell cycle progression. In summary, we conclude that the novel series of N- substituted benzimidazole derivatives can serve as a prototype molecule for further development of a new class of anti-cancer agents.

1. Townsend, L. B.; Wise, D. S., The Synthesis and Chemistry of Certain Anthelmintic Benzimidazoles. Parasitol Today 1990, 6 (4), 107-112.
2. Chaudhari, V. K.; Pathak, D.; Singh, S., Benzimidazole: As potential biologically active agent. Int. Res. J. Pharm. 2014, 5 (12), 861-875.
3. Tuncbilek, M.; Kiper, T.; Altanlar, N., Synthesis and in vitro antimicrobial activity of some novel substituted benzimidazole derivatives having potent activity against MRSA. Eur J Med Chem 2009, 44 (3), 1024-1033.
4. Shingalapur, R. V.; Hosamani, K. M.; Keri, R. S., Synthesis and evaluation of in vitro anti-microbial and anti-tubercular activity of 2-styryl benzimidazoles. Eur J Med Chem 2009, 44 (10), 4244-4248.
5. Zhang, H. Z.; Damu, G. L. V.; Cai, G. X.; Zhou, C. H., Design, synthesis and antimicrobial evaluation of novel benzimidazole type of Fluconazole analogues and their synergistic effects with Chloromycin, Norfloxacin and Fluconazole. Eur J Med Chem 2013, 64, 329-344.
6. Hernandez-Luis, F.; Hernandez-Campos, A.; Castillo, R.; Navarrete-Vazquez, G.; Soria-Arteche, O.; Hernandez-Hernandez, M.; Yepez-Mulia, L., Synthesis and biological activity of 2-(trifluoromethyl)-1H-benzimidazole derivatives against some protozoa and Trichinella spiralis. Eur J Med Chem 2010, 45 (7), 3135-3141.
7. Valdez-Padilla, D.; Rodriguez-Morales, S.; Hernandez-Campos, A.; Hernandez-Luis, F.; Yepez-Mulia, L.; Tapia-Contreras, A.; Castillo, R., Synthesis and antiprotozoal activity of novel 1-methylbenzimidazole derivatives. Bioorgan Med Chem 2009, 17 (4), 1724-1730.
8. Rida, S. M.; El-Hawash, S. A. M.; Fahmy, H. T. Y.; Hazzaa, A. A.; El-Meligy, M. M. M., Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation of in vitro anti-HIV-1, anticancer and antimicrobial activities. Arch Pharm Res 2006, 29 (10), 826-833.
9. Luo, Y.; Yao, J. P.; Yang, L.; Feng, C. L.; Tang, W.; Wang, G. F.; Zuo, J. P.; Lu, W., Design and synthesis of novel benzimidazole derivatives as inhibitors of hepatitis B virus. Bioorgan Med Chem 2010, 18 (14), 5048-5055.
10. Singla, P.; Luxami, V.; Paul, K., Benzimidazole-biologically attractive scaffold for protein kinase inhibitors. Rsc Adv 2014, 4 (24), 12422-12440.
11. Achar, K. C. S.; Hosamani, K. M.; Seetharamareddy, H. R., In-vivo analgesic and anti-inflammatory activities of newly synthesized benzimidazole derivatives. Eur J Med Chem 2010, 45 (5), 2048-2054.
12. Refaat, H. M., Synthesis and anticancer activity of some novel 2-substituted benzimidazole derivatives. Eur J Med Chem 2010, 45 (7), 2949-2956.
13. Azam, M.; Khan, A. A.; Al-Resayes, S. I.; Islam, M. S.; Saxena, A. K.; Dwivedi, S.; Musarrat, J.; Trzesowska-Kruszynska, A.; Kruszynski, R., Synthesis and characterization of 2-substituted benzimidazoles and their evaluation as anticancer agent. Spectrochim Acta A 2015, 142, 286-291.
14. Di Carlo, G.; Mascolo, N.; Izzo, A. A.; Capasso, F., Flavonoids: Old and new aspects of a class of natural therapeutic drugs. Life Sci 1999, 65 (4), 337-353.
15. Nowakowska, Z., A review of anti-infective and anti-inflammatory chalcones. Eur J Med Chem 2007, 42 (2), 125-137.
16. Pettit, G. R.; Rhodes, M. R.; Herald, D. L.; Hamel, E.; Schmidt, J. M.; Pettitt, R. K., Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-4. J Med Chem 2005, 48 (12), 4087-4099.
17. Sivakumar, P. M.; Ganesan, S.; Veluchamy, P.; Doble, M., Novel chalcones and 1,3,5-triphenyl-2-pyrazoline derivatives as antibacterial agents. Chem Biol Drug Des 2010, 76 (5), 407-411.
18. Agarwal, A.; Srivastava, K.; Puri, S. K.; Chauhan, P. M. S., Synthesis of substituted indole derivatives as a new class of antimalarial agents. Bioorg Med Chem Lett 2005, 15 (12), 3133-3136.
19. Suwito, H.; Jumina; Mustofa; Pudjiastuti, P.; Fanani, M. Z.; Kimata-Ariga, Y.; Katahira, R.; Kawakami, T.; Fujiwara, T.; Hase, T.; Sirat, H. M.; Puspaningsih, N. N. T., Design and Synthesis of Chalcone Derivatives as Inhibitors of the Ferredoxin - Ferredoxin-NADP(+) Reductase Interaction of Plasmodium falciparum: Pursuing New Antimalarial Agents. Molecules 2014, 19 (12), 21473-21488.
20. Boeck, P.; Leal, P. C.; Yunes, R. A.; Cechinel, V.; Lopez, S.; Sortino, M.; Escalante, A.; Furlan, R. L. E.; Zacchino, S., Antifungal activity and studies on mode of action of novel xanthoxyline-derived chalcones. Arch Pharm 2005, 338 (2-3), 87-95.
21. Cheenpracha, S.; Karalai, C.; Ponglimanont, C.; Subhadhirasakul, S.; Tewtrakul, S., Anti-HIV-1 protease activity of compounds from Boesenbergia pandurata. Bioorgan Med Chem 2006, 14 (6), 1710-1714.
22. Mateeva, N.; Gangapuram, M.; Mazzio, E.; Eyunni, S.; Soliman, K. F. A.; Redda, K. K., Biological evaluation of synthetic chalcone and flavone derivatives as anti-inflammatory agents. Med Chem Res 2015, 24 (4), 1672-1680.
23. Kim, T. H.; Seo, W. D.; Ryu, H. W.; Seo, H. R.; Jin, Y. B.; Lee, M.; Ji, Y. H.; Park, K. H.; Lee, Y. S., Anti-tumor effects by a synthetic chalcone compound is mediated by c-Myc-mediated reactive oxygen species production. Chem-Biol Interact 2010, 188 (1), 111-118.
24. Quintin, J.; Desrivot, J.; Thoret, S.; Le Menez, P.; Cresteil, T.; Lewin, G., Synthesis and biological evaluation of a series of tangeretin-derived chalcones. Bioorg Med Chem Lett 2009, 19 (1), 167-169.
25. Kamal, A.; Prabhakar, S.; Ramaiah, M. J.; Reddy, P. V.; Reddy, C. R.; Mallareddy, A.; Shankaraiah, N.; Reddy, T. L. N.; Pushpavalli, S. N. C. V. L.; Pal-Bhadra, M., Synthesis and anticancer activity of chalcone-pyrrolobenzodiazepine conjugates linked via 1,2,3-triazole ring side-armed with alkane spacers. Eur J Med Chem 2011, 46 (9), 3820-3831.
26. Modzelewska, A.; Pettit, C.; Achanta, G.; Davidson, N. E.; Huang, P.; Khan, S. R., Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorgan Med Chem 2006, 14 (10), 3491-3495.
27. Wan, M. S.; Xu, L. Y.; Hua, L.; Li, A. L.; Li, S. Q.; Lu, W. J.; Pang, Y.; Cao, C. B.; Liu, X. G.; Jiao, P., Synthesis and evaluation of novel isoxazolyl chalcones as potential anticancer agents. Bioorg Chem 2014, 54, 38-43.
28. Solomon, V. R.; Hu, C. K.; Lee, H., Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorgan Med Chem 2009, 17 (21), 7585-7592.
29. He, S. W.; Hong, Q. M.; Lai, Z.; Yang, D. X.; Ting, P. C.; Kuethe, J. T.; Cernak, T. A.; Dykstra, K. D.; Sperbeck, D. M.; Wu, Z. C.; Yu, Y.; Yang, G. X.; Jian, T. Y.; Liu, J.; Guiadeen, D.; Krikorian, A. D.; Sonatore, L. M.; Wiltsie, J.; Liu, J. Q.; Gorski, J. N.; Chung, C. C.; Gibson, J. T.; Lisnock, J.; Xiao, J. Y.; Wolff, M.; Tong, S. X.; Madeira, M.; Karanam, B. V.; Shen, D. M.; Balkovec, J. M.; Pinto, S.; Nargund, R. P.; DeVita, R. J., Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety. Acs Med Chem Lett 2014, 5 (10), 1082-1087.
30. Shaharyar, M.; Abdullah, M. M.; Bakht, M. A.; Majeed, J., Pyrazoline bearing benzimidazoles: Search for anticancer agent. Eur J Med Chem 2010, 45 (1), 114-119.
31. Ouattara, M.; Sissouma, D.; Kone, M. W.; Menan, H. E.; Toure, S. A.; Ouattara, L., Synthesis and anthelmintic activity of some hybrid Benzimidazolyl-chalcone derivatives. Trop J Pharm Res 2011, 10 (6), 767-775.
32. Reddy, V. M.; Reddy, K. R., Synthesis and biological evaluation of some novel-3-(5-substituted benzimidazol-2-yl)-5-arylisoxazolines. Chinese Chem Lett 2010, 21 (10), 1145-1148.
33. Mathew, B.; Suresh, J.; Vinod, D., Antitumour activity of 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-substituted phenylprop-2-en-1-ylidene] pyrimidine-2,4,6(1H,3H,5H)-triones against Dalton's ascitic lymphoma in mice. Med Chem Res 2013, 22 (8), 3911-3917.
34. Woo, H. B.; Eom, Y. W.; Park, K. S.; Ham, J.; Ahn, C. M.; Lee, S., Synthesis of substituted benzimidazolyl curcumin mimics and their anticancer activity. Bioorg Med Chem Lett 2012, 22 (2), 933-936.
35. Hayes, M. E.; Wallace, G. A.; Grongsaard, P.; Bischoff, A.; George, D. M.; Miao, W. Y.; McPherson, M. J.; Stoffel, R. H.; Green, D. W.; Roth, G. P., Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3. Bioorg Med Chem Lett 2008, 18 (5), 1573-1576.
36. Mehboob, S.; Song, J. H.; Hevener, K. E.; Su, P. C.; Boci, T.; Brubaker, L.; Truong, L.; Mistry, T.; Deng, J. P.; Cook, J. L.; Santarsiero, B. D.; Ghosh, A. K.; Johnson, M. E., Structural and biological evaluation of a novel series of benzimidazole inhibitors of Francisella tularensis enoyl-ACP reductase (FabI). Bioorg Med Chem Lett 2015, 25 (6), 1292-1296.
37. Sharma, A.; Luxami, V.; Paul, K., Synthesis, single crystal and antitumor activities of benzimidazole-quinazoline hybrids. Bioorg Med Chem Lett 2013, 23 (11), 3288-3294.
38. Hwu, J. R.; Hsu, M. H.; Huang, R. C. C., New nordihydroguaiaretic acid derivatives as anti-HIV agents. Bioorg Med Chem Lett 2008, 18 (6), 1884-1888.
39. Orjales, A.; Alonso-Cires, L.; Lopez-Tudanca, P.; Tapia, I.; Mosquera, R.; Labeaga, L., Benzimidazole-2-carboxylic acid amides and esters: a new structural class of 5-HT(3) ligands. Eur J Med Chem 1999, 34 (5), 415-422.
40. Saleshier, F. M.; Suresh.S; .N, A.; JubinaKarim; Madhu.C.Divakar, Design, docking and synthesis of some 6-benzimidazoyl pyrans and
screening of their anti tubercular activity. European Journal of Experimental Biology 2011, 1 (2), 150-159.
41. V., D. J.; Chavan Rashmi S.; Chaudhari Nileshwari S; Patil, D. S. T., A short review on chemistry and potential activities of benzimidazole molecule. IJPT 2013, 5 (1), 2477-2494.
42. Noolvi, M. N.; Patel, H. M.; Bhardwaj, V.; Chauhan, A., Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. Eur J Med Chem 2011, 46 (6), 2327-2346.
43. Carpino, L. A., A Simple Preparation of Active Manganese Dioxide from Activated Carbon. J Org Chem 1970, 35 (11), 3971-1372.